A patient-derived lung-on-chip model to evaluate on-target/off-tumour toxicity of the therapeutic FOLR1-targeting T-Cell Bispecific antibody

G. Raggi (Bern, Switzerland), L. Froment (Bern, Switzerland), V. Micallef (Basel, Switzerland), N. Roldan (Bern, Switzerland), L. Cabon (Basel, Switzerland), N. Hobi (Bern, Switzerland)

Source: Virtual Congress 2021 – In vitro modelling of lung disease: reach out to the next dimension
Session: In vitro modelling of lung disease: reach out to the next dimension
Session type: E-poster
Number: 2054

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
G. Raggi (Bern, Switzerland), L. Froment (Bern, Switzerland), V. Micallef (Basel, Switzerland), N. Roldan (Bern, Switzerland), L. Cabon (Basel, Switzerland), N. Hobi (Bern, Switzerland). A patient-derived lung-on-chip model to evaluate on-target/off-tumour toxicity of the therapeutic FOLR1-targeting T-Cell Bispecific antibody. 2054

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
PP129 – Safety evaluation of cancer immunotherapy in a lung-on-chip model: the therapeutic FOLR1 targeting T Cell Bispecific antibody
Source: ERS Lung Science Conference 2021
Year: 2021

B-cell suppressive therapy and monoclonal antibodies in CTD: does one size fit all?
Source: Virtual Congress 2020 – Rheumatology: understanding connective tissue disease in patients with interstitial lung disease
Year: 2020


Reversing the suppression of T-cells: the role of monoclonal antibodies
Source: International Congress 2015 – Stop immune tolerance in lung cancer!
Year: 2015



Rapid reversal of radiation-induced murine pneumonitis by treatment with the anti-CTGF monoclonal antibody FG-3019
Source: Annual Congress 2011 - Experimental models and research in diffuse parenchymal lung diseases
Year: 2011

Late Breaking Abstract - Preclinical study of anti-interleukin-4 alpha single domain antibody with therapeutic potential in asthma by oral inhalation
Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies
Year: 2019


Endothelial eNAMPT amplifies pre-clinical acute lung injury: efficacy of an eNAMPT-neutralising monoclonal antibody
Source: Eur Respir J, 57 (5) 2002536; 10.1183/13993003.02536-2020
Year: 2021



Efficacy and safety of anti-PD-L1 antibody in NSCLC patients who previously treated with anti PD-1 antibodies
Source: International Congress 2019 – Treatment of lung cancer
Year: 2019


Impact of age on the efficacy of anti-IL-5 monoclonal antibodies in severe asthmatics
Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies
Year: 2019

Late Breaking Abstract - Anti-IL-4 and anti-IL-13 dual vaccination using Kinoid technology prevents development of allergic asthma in mice
Source: International Congress 2019 – New towards old therapies in airway diseases
Year: 2019




Phase 1 study of a novel, prolonged-action anti-IL-5 monoclonal antibody in asthma
Source: Virtual Congress 2021 – Clinical trials in airway diseases: novel treatments and new evidence
Year: 2021



Specific monoclonal antibody to detect the C-terminal peptide of alpha1-antitrypsin: clinical importance
Source: International Congress 2019 – Chronic cough, a1-antitrypsin deficiency and other conditions
Year: 2019

A novel anti-IgE immunotherapeutic, RP01, induces anti-IgE antibodies in human subjects; data from a phase I study
Source: Eur Respir J 2007; 30: Suppl. 51, 622s
Year: 2007

Novel inhaled delivery of anti-IL-13 mAb (Fab fragment): preclinical efficacy in allergic asthma
Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies
Year: 2017

A specific monoclonal antibody targeting C-36 peptide of alpha1-antitrypsin as a tool in respiratory research
Source: Virtual Congress 2021 – Biomarkers for the management of bronchial obstructive diseases
Year: 2021


Sarcoidosis complicating anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody biotherapy
Source: Eur Respir J 2013; 41: 246-247
Year: 2013


Preclinical development of an IL-13 neutralising antibody, CAT-354, for the treatment of human asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 367s
Year: 2005

Effects of anti-M1 prime monoclonal antibody, MEMP1972A following allergen challenge in patients with mild asthma
Source: Annual Congress 2012 - New bronchodilators and other novel drugs for asthma and COPD
Year: 2012

Efficacy of inhaled anti-IL-13 mAb in a mouse model of asthma
Source: Annual Congress 2011 - Experimental modulation of airway inflammation
Year: 2011